Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 696

1.
2.

A novel nicotinic acetylcholine receptor subtype in basal forebrain cholinergic neurons with high sensitivity to amyloid peptides.

Liu Q, Huang Y, Xue F, Simard A, DeChon J, Li G, Zhang J, Lucero L, Wang M, Sierks M, Hu G, Chang Y, Lukas RJ, Wu J.

J Neurosci. 2009 Jan 28;29(4):918-29. doi: 10.1523/JNEUROSCI.3952-08.2009.

3.

α7 nicotinic acetylcholine receptors in Alzheimer's disease: neuroprotective, neurotrophic or both?

Hernandez CM, Dineley KT.

Curr Drug Targets. 2012 May;13(5):613-22. Review.

PMID:
22300028
4.

Impaired hippocampal acetylcholine release parallels spatial memory deficits in Tg2576 mice subjected to basal forebrain cholinergic degeneration.

Laursen B, Mørk A, Plath N, Kristiansen U, Bastlund JF.

Brain Res. 2014 Jan 16;1543:253-62. doi: 10.1016/j.brainres.2013.10.055. Epub 2013 Nov 11.

PMID:
24231553
5.

Deletion of the alpha 7 nicotinic acetylcholine receptor gene improves cognitive deficits and synaptic pathology in a mouse model of Alzheimer's disease.

Dziewczapolski G, Glogowski CM, Masliah E, Heinemann SF.

J Neurosci. 2009 Jul 8;29(27):8805-15. doi: 10.1523/JNEUROSCI.6159-08.2009.

6.

Nicotine prevents synaptic impairment induced by amyloid-β oligomers through α7-nicotinic acetylcholine receptor activation.

Inestrosa NC, Godoy JA, Vargas JY, Arrazola MS, Rios JA, Carvajal FJ, Serrano FG, Farias GG.

Neuromolecular Med. 2013 Sep;15(3):549-69. doi: 10.1007/s12017-013-8242-1. Epub 2013 Jul 11.

PMID:
23842742
7.

Transgenic mice as a model of pre-clinical Alzheimer's disease.

Ferretti MT, Partridge V, Leon WC, Canneva F, Allard S, Arvanitis DN, Vercauteren F, Houle D, Ducatenzeiler A, Klein WL, Glabe CG, Szyf M, Cuello AC.

Curr Alzheimer Res. 2011 Feb;8(1):4-23.

PMID:
21143159
8.

Reversible pathologic and cognitive phenotypes in an inducible model of Alzheimer-amyloidosis.

Melnikova T, Fromholt S, Kim H, Lee D, Xu G, Price A, Moore BD, Golde TE, Felsenstein KM, Savonenko A, Borchelt DR.

J Neurosci. 2013 Feb 27;33(9):3765-79. doi: 10.1523/JNEUROSCI.4251-12.2013.

10.

Amyloid-beta causes memory impairment by disturbing the JAK2/STAT3 axis in hippocampal neurons.

Chiba T, Yamada M, Sasabe J, Terashita K, Shimoda M, Matsuoka M, Aiso S.

Mol Psychiatry. 2009 Feb;14(2):206-22. doi: 10.1038/mp.2008.105. Epub 2008 Sep 23.

PMID:
18813209
11.

Intraneuronal beta-amyloid accumulation in the amygdala enhances fear and anxiety in Alzheimer's disease transgenic mice.

España J, Giménez-Llort L, Valero J, Miñano A, Rábano A, Rodriguez-Alvarez J, LaFerla FM, Saura CA.

Biol Psychiatry. 2010 Mar 15;67(6):513-21. doi: 10.1016/j.biopsych.2009.06.015. Epub 2009 Aug 7.

PMID:
19664757
12.
13.

A novel nicotinic mechanism underlies β-amyloid-induced neuronal hyperexcitation.

Liu Q, Xie X, Lukas RJ, St John PA, Wu J.

J Neurosci. 2013 Apr 24;33(17):7253-63. doi: 10.1523/JNEUROSCI.3235-12.2013.

14.

Berberine ameliorates β-amyloid pathology, gliosis, and cognitive impairment in an Alzheimer's disease transgenic mouse model.

Durairajan SS, Liu LF, Lu JH, Chen LL, Yuan Q, Chung SK, Huang L, Li XS, Huang JD, Li M.

Neurobiol Aging. 2012 Dec;33(12):2903-19. doi: 10.1016/j.neurobiolaging.2012.02.016. Epub 2012 Mar 27.

PMID:
22459600
15.

Corticotrophin releasing factor accelerates neuropathology and cognitive decline in a mouse model of Alzheimer's disease.

Dong H, Murphy KM, Meng L, Montalvo-Ortiz J, Zeng Z, Kolber BJ, Zhang S, Muglia LJ, Csernansky JG.

J Alzheimers Dis. 2012;28(3):579-92. doi: 10.3233/JAD-2011-111328.

16.

Early increases in soluble amyloid-β levels coincide with cholinergic degeneration in 3xTg-AD mice.

Girão da Cruz MT, Jordão J, Dasilva KA, Ayala-Grosso CA, Ypsilanti A, Weng YQ, Laferla FM, McLaurin J, Aubert I.

J Alzheimers Dis. 2012;32(2):267-72. doi: 10.3233/JAD-2012-100732.

PMID:
22776965
17.

Ryanodine receptor blockade reduces amyloid-β load and memory impairments in Tg2576 mouse model of Alzheimer disease.

Oulès B, Del Prete D, Greco B, Zhang X, Lauritzen I, Sevalle J, Moreno S, Paterlini-Bréchot P, Trebak M, Checler F, Benfenati F, Chami M.

J Neurosci. 2012 Aug 22;32(34):11820-34.

18.

Temporal changes of CD68 and α7 nicotinic acetylcholine receptor expression in microglia in Alzheimer's disease-like mouse models.

Matsumura A, Suzuki S, Iwahara N, Hisahara S, Kawamata J, Suzuki H, Yamauchi A, Takata K, Kitamura Y, Shimohama S.

J Alzheimers Dis. 2015;44(2):409-23. doi: 10.3233/JAD-141572.

PMID:
25352454
19.

Elevation of brain magnesium prevents and reverses cognitive deficits and synaptic loss in Alzheimer's disease mouse model.

Li W, Yu J, Liu Y, Huang X, Abumaria N, Zhu Y, Huang X, Xiong W, Ren C, Liu XG, Chui D, Liu G.

J Neurosci. 2013 May 8;33(19):8423-41. doi: 10.1523/JNEUROSCI.4610-12.2013. Retraction in: J Neurosci. 2014 Apr 16;34(16):5733.

20.

Cannabinoid receptor 1 deficiency in a mouse model of Alzheimer's disease leads to enhanced cognitive impairment despite of a reduction in amyloid deposition.

Stumm C, Hiebel C, Hanstein R, Purrio M, Nagel H, Conrad A, Lutz B, Behl C, Clement AB.

Neurobiol Aging. 2013 Nov;34(11):2574-84. doi: 10.1016/j.neurobiolaging.2013.05.027. Epub 2013 Jul 6.

PMID:
23838176
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk